Monitoring of Patients With Low-grade Gliomas Using Circulating miRNA (GLIBAMIR)

September 23, 2024 updated by: University Hospital, Caen

With around 3,400 cases per year in France, diffuse gliomas are the most common primary tumours of the central nervous system. Their grade varies from 2 to 4. Whatever the grade, their prognosis is poor, because tumour recurrence is systematic, because no personalised medicine is available for the treatment of these cancers, and because the tools for monitoring recurrence are imperfect. Treatment of diffuse gliomas is based on removal of as much of the tumour as possible, whatever its grade. Surgery is followed by radiotherapy and chemotherapy depending on the grade and quality of the excision. In the event of recurrence, the patient may be offered second-line chemotherapy or further surgery. During and after treatment, patients are regularly monitored by MRI in order to detect any recurrence as early as possible and propose a new treatment. However, for grade 2 and 3 gliomas, MRI monitoring is imperfect because it cannot detect tumour recurrence at an early stage. Initiation of new treatment at the time of recurrence, which is inevitable, is therefore often delayed, which is harmful for patients.

It is therefore vital to identify a reliable, easy-to-use and non-invasive biomarker that can be used to monitor patients undergoing surgery for grade 2 and 3 diffuse gliomas, and thus enable earlier diagnosis of recurrence. These biomarkers could be microRNAs.

MicroRNAs are small non-coding RNAs involved in the regulation of genes and, consequently, of the intracellular signalling pathways that govern cell behaviour. They are therefore widely implicated in oncogenesis, and in particular in the mechanisms that promote tumour migration, invasion and proliferation.

Several preliminary studies have shown that serum levels of pro-oncogenic microRNAs correlate with tumour rates in gliomas. No study has investigated the possibility of using them to detect tumour recurrence earlier in grade 2 and 3 gliomas.

With this study, the investigators hope to use pro-oncogenic microRNAs to monitor glioma patients and diagnose early recurrence in grade 2 and 3 gliomas.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Diagnostic test: Blood sample

Detailed Description

Diffuse gliomas are the most common primary tumours of the central nervous system, representing around 3,400 cases per year in France (Defossez et al., 2019). Their grade varies from 2 to 4. Whatever the grade, their prognosis is poor (Grade 2: median survival > 10 years, Grade 3: median survival around 5 years, Grade 4: median survival < 2 years) (Yang et al., 2016).

Grade 2 and 3 diffuse gliomas are rarer than Grade 4 gliomas, and their treatment is based on removing the tumour as completely as possible while preserving the patient's neurological function. This surgical treatment is sometimes followed by chemotherapy and/or radiotherapy, depending on the grade of the tumour and the quality of the excision. Recurrence of grade 2 and 3 gliomas after surgery is systematic and generally occurs within 2 to 5 years of surgery (Pineda et al., 2023). Gliomas are infiltrating tumours in which tumour cells are found infiltrating the cerebral parenchyma up to 2 cm from the periphery of the tumour as seen on MRI, which explains their inevitable recurrence, since surgery cannot be wide (it is difficult to create "safety margins" in the brain) and will invariably leave tumour cells in situ (Pallud et al., 2013).

In the event of recurrence, the patient may be offered second-line chemotherapy or further surgery.

Patients are monitored for recurrence by regular brain MRI, but this is imperfect because it is difficult to detect tumour recurrence (which appears as a slow increase in the FLAIR hypersignal). If there is any doubt about a recurrence, MRI is repeated 2 to 3 months later to clearly identify the recurrence. This confirmation wastes time in the management of patients who are treated too late.

To improve the diagnosis of recurrence in these patients, it is vital to identify a reliable, easy-to-use and non-invasive biomarker for monitoring patients undergoing surgery for diffuse glioma. MicroRNAs could be the tool sorely lacking in the monitoring of glioma patients.

MicroRNAs are small non-coding RNAs involved in the post-transcriptional regulation of genes and, consequently, of the intracellular signalling pathways that govern cell behaviour (Komatsu et al., 2023). They are widely implicated in oncogenesis, and in particular in the mechanisms promoting cell migration, invasion and proliferation (Romano et al., 2021).

Several preliminary studies have shown that the serum level of pro-oncogenic microRNAs correlates with the tumour rate in gliomas (Jones et al., 2021; Levallet et al., 2022; Morokoff et al., 2020). Morokoff's study showed encouraging but insufficient results on the possibility of using microRNAs to diagnose recurrence in grade 2 and 3 gliomas. These results need to be consolidated prospectively, using homogeneous samples from all patients.

MAIN OBJECTIVE

To describe the time course of plasma levels of pro-oncogenic microRNAs after surgery for grade 2 or 3 glioma, in order to assess whether they can detect recurrence earlier than MRI. The investigators hope to identify microRNA(s) with :

a stable profile in subjects without recurrence
a change in their level(s) in the event of recurrence.

SECONDARY OBJECTIVES

To assess the correlation between :
1. tumour and plasma levels at Day 0, for each microRNA
2. the tumour levels at D0 of the microRNAs in pairs
3. plasma levels at Day 0 and Day 4 of paired microRNAs.
Assess the correlation between tumour volume at D0 and :
1. tumour rate at Day 0, for each microRNA
2. plasma levels at Day 0 and Day 4, for each microRNA
Assess the relationship between plasma levels of each microRNA (at Day 0 and Day 4) and recurrence-free survival.
To assess the relationship between tumour levels at Day 0 of each microRNA and recurrence-free survival.

PIONEERING NATURE Most research projects aimed at improving the follow-up of gliomas are based on improving imaging parameters (perfusion sequences, PET-MRI). These examinations are often difficult to access, with appointment times delaying treatment. Diagnosis of recurrence depends on the radiologist. In addition, not all teams are trained in perfusion analysis, and nuclear medicine teams are rare in France.

The investigator are proposing here an original approach (blood sampling), innovative (microRNA assay) and above all simple to be used routinely to improve the follow-up of these patients.

Study Type

Observational

Enrollment (Estimated)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

France
- - Caen, France, 14000
    - Recruiting
    - Arthur LECLERC
    - Contact:
      
      Arthur LECLERC, MD
      
      Phone Number: +33231064603
      
      Email: leclerc-art@chu-caen.fr
    - Contact:
      
      Guénaelle LEVALLET, MD, PhD
      
      Phone Number: +33231063134
      
      Email: levallet-g@chu-caen.fr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Adult
Older Adult

Accepts Healthy Volunteers

Sampling Method

Non-Probability Sample

Study Population

Major patient suffered from a grade 2-3 diffuse glioma

Description

Inclusion Criteria:

Major patient
Suffered from a grade 2-3 diffuse glioma
Surgery in the neurosurgery department of Caen University Hospital
Patient affiliated to a social security scheme
Patient followed at Caen University Hospital
No opposition from the patient

Exclusion Criteria:

Patients who have undergone biopsy (lack of material for the study, limited value of monitoring for these patients without surgical excision)
Patients with grade 1 circumscribed glioma
Patients with grade 4 glioma
Other non-glial histologies, glioneuronal histology
Minor patients
Patient not affiliated to a social security scheme
Major under guardianship or protected

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasma levels of each microRNA at each time point Time Frame: Day 0, Day 4, then every 6 months for 5 years	Plasma levels of each microRNA at each time point	Day 0, Day 4, then every 6 months for 5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tumor volume Time Frame: Day 0, Day 4, then every 6 months for 5 years	Tumor volume (cm3)	Day 0, Day 4, then every 6 months for 5 years
Overall Survival Time Frame: 60 months	OS	60 months
Progression free survival Time Frame: 60 months	PFS	60 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Caen

Collaborators

Région Normandie

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 25, 2024

Primary Completion (Actual)

April 25, 2024

Study Completion (Estimated)

April 25, 2030

Study Registration Dates

First Submitted

July 30, 2024

First Submitted That Met QC Criteria

September 23, 2024

First Posted (Actual)

September 24, 2024

Study Record Updates

Last Update Posted (Actual)